Posted by: ctraderd | July 17, 2012

Vivus’ Drug Qsymia Approved

On July 17, 2012, Vivus, Inc. (VVUS) had a PDUFA for their drug Qsymia, also known as Qnexa, and found out that it had been approved. The approval news happened in the aftermarket and, as of 7:00 P.M. EST, VVUS had fallen –1.81 for a total of –6.84%. In the open market, VVUS had already fell –2.24 for a total of –7.82% on Tuesday.

VVUS’ drug Qsymia is a fat busting drug and has two major competitors, Arena Pharmaceuticals (ARNA), and Orexigen Therapeutics (OREX). ARNA got their drug, Belviq, approved on June 27, 2012 and OREX does not have another PDUFA until 2014 at least. Upon approval of Qsymia, ARNA fell -.80 for a total of –7.24% and OREX went up +.46 for a total of +6.44%.

VVUS(2)

FDA Press Release:

MOUNTAIN VIEW, Calif., July 17, 2012 /PRNewswire/ — VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved Qsymia™ (pronounced Kyoo sim ee’ uh) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia).

"Qsymia is the first FDA-approved once daily combination treatment for patients struggling with obesity," said Peter Tam, President of VIVUS. "The degree and severity of obesity and the lack of effective pharmacological interventions that we face as a society were two primary reasons for the development of Qsymia. We are pleased with FDA’s decision today because patients and physicians now have another treatment option available to them. It is expected that Qsymia will be available in the fourth quarter of 2012."

The safety and efficacy of Qsymia were evaluated in two multicenter, phase 3 trials that included severely obese patients (the EQUIP study), and overweight or obese patients with at least two weight-related comorbidities, such as hypertension, hypertriglyceridemia, type 2 diabetes, or central adiposity (the CONQUER study). The average weight loss in EQUIP was 10.9% on Qsymia 15 mg/92 mg and 1.6% for placebo (ITT-LOCF, p < 0.0001). The average weight loss in CONQUER was 9.8% on Qsymia 15 mg/92 mg, 7.8% on Qsymia 7.5 mg/46 mg and 1.2% for placebo (ITT-LOCF, p < 0.0001).

The most common adverse reactions for patients treated with Qsymia included tingling sensation of hands and feet, dizziness, altered taste, insomnia, constipation and dry mouth.

Qsymia was approved with a Risk Evaluation and Mitigation Strategy (REMS) with a goal of informing prescribers and female patients of reproductive potential about an increased risk of orofacial clefts in infants exposed to Qsymia during the first trimester of pregnancy, the importance of pregnancy prevention for females of reproductive potential receiving Qsymia and the need to discontinue Qsymia immediately if pregnancy occurs. The Qsymia REMS program includes a Medication Guide, Healthcare Provider training, distribution through certified pharmacies, implementation system and a time table for assessments.

As part of the approval of Qsymia, VIVUS is committed to conduct post-marketing studies. The company will conduct a study to assess the long-term treatment effect of Qsymia on the incidence of major adverse cardiovascular events in overweight and obese subjects with confirmed cardiovascular disease, studies to assess the safety and efficacy of Qsymia for weight management in obese pediatric and adolescent subjects, studies to assess drug utilization and pregnancy exposure, a study to assess renal function, as well as animal and in vitro studies.

Source: http://ir.vivus.com/releasedetail.cfm?ReleaseID=692685

Advertisements

Responses

  1. It really does appear that this qsymia is going to be a huge success. Let’s hope it does not end up causing too many health issues for people.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Categories

%d bloggers like this: